Objective: To assess intermittent pneumatic compression (IPC) in the prevention of venous thromboembolism (VTE). Methods: The authors randomly allocated patients with a documented intracerebral hemorrhage (ICH) to elastic stockings (ES) alone or combined with IPC. The primary outcome was a combined criteria assessed at day 10: a symptomatic and well-documented VTE, or a death arising before day 10 and related to pulmonary embolism (PE), or an asymptomatic deep vein thrombosis (DVT) of the lower limbs detected by compression ultrasonography (CUS). Outcome assessment was blinded. Results: One hundred fifty-one patients were randomized; 133 (88%) patients were evaluated at day 10. No clinical suspicion of VTE arose before day 10. Fourteen patients died before having a CUS but no death was definitely related to PE. Fourteen asymptomatic DVT were detected by CUS: three (4.7%) in the ES ϩ IPC group (all distal) and 11 (15.9%) in the ES group (three proximal and eight distal). ES combined with IPC is associated with a reduced risk of asymptomatic DVT compared to ES alone: relative risk, 0.29 (95% CI 0.08 to 1.00). Conclusions: Asymptomatic deep vein thrombosis (DVT) was detected at day 10 in 15.9% of patients wearing elastic stockings alone. Intermittent pneumatic compression significantly decreased the occurrence of asymptomatic DVT for patients with intracerebral hemorrhage.
NEUROLOGY 2005;65: [865] [866] [867] [868] [869] Venous thromboembolism (VTE) frequently occurs in the course of ischemic stroke and approximately 5% of early deaths following stroke are attributed to pulmonary embolism (PE). 1 One stroke out of five is hemorrhagic. 2 Surprisingly, no data on the occurrence of VTE are available for patients who experienced intracerebral hemorrhage (ICH). The prevention of VTE in those patients is challenging because the use of anticoagulants is potentially hazardous and no randomized trial investigating mechanical devices has been published. 3 The early use of heparin in these patients has appeared safe for the prevention of thromboembolic complications. 4 On the other hand, the 7th American College of Chest Physicians (ACCP) consensus conference 3 recommends the use of mechanical prophylaxis in certain patient groups, especially in those at high risk for bleeding. Indeed, patients with ICH are at high risk for bleeding, at least in the first 48 hours. Therefore, consensus statements are based on extrapolation from other settings. Intermittent pneumatic compression (IPC) and elastic stockings (ES) have been evaluated in neurosurgical patients, [5] [6] [7] [8] [9] [10] [11] most of them with brain tumors, and were found superior compared with no treatment.
We report the results of a randomized trial that compared IPC of the legs vs ES to prevent VTE for patients who had experienced acute ICH.
Methods. All patients referred to Brest University Hospital between February 2002 and December 2003 for an acute ICH, confirmed by CT or MRI, were identified through the daily neurosurgical briefing. A research assistant attended the briefing daily, gathered the information, and approached potential participants and care providers. Patients were hospitalized either in intensive care units or in medical wards (see appendix).
Eligibility criteria were: age over 18 years, traumatic or spontaneous ICH with or without subarachnoidal hemorrhage, and written informed consent given by the patient or relative.
Exclusion criteria were: extra-or subdural hematomas, traumatic ICH due to polytrauma including the lower limbs, hemorrhagic transformation of ischemic infarct and vasculitis (when the diagnostic was established), patient or relative refusal, a deep vein thrombosis (DVT) within the previous 3 months, a lower-limb arteriopathy with an ankle-to-arm systolic pressure index Ͻ0.70, a venous graft, a wound in the lower limb related either to a vascular disease (ulcer) or a trauma, a "do not resuscitate" order, and a Ͼ24-hour delay since hospital admission.
Eligible patients were asked to participate in the trial. When the patient could not give written informed consent, a relative was approached. Pending patient's final decision, the patient was enrolled with the consent of the relative. The Local Ethics Committee approved the protocol. The study was carried out according to the Helsinki Declaration and Good Clinical Practice Guidelines.
Demographic data, Glasgow coma score, mobility status, and operative procedure were recorded. Risk factors for ICH were evaluated. Hypertension was defined as stated by the general practitioner or on the basis of a recorded antihypertensive treatment. A heavy alcohol drinker was defined as an average daily intake over the past 3 months of Ն40 g of alcohol. Patients and their proxies were asked for anticoagulant and antiplatelet therapies. Risk factors for VTE were also evaluated: active cancer, personal or familial history of VTE, varicose veins, hormonal treatment, or hospitalization in the past 3 months. Medical records were checked and general practitioner was interviewed.
Intervention and randomization process. Graded ES were put on as soon as the patient was admitted to standard care. Eligible patients were randomly assigned within 48 hours of admission to hospital to receive ES alone (TED) or ES plus IPC (SC Response Controller). A trained research nurse performed measurements and checked that adequately sized ES (TED) fitting leg lengths were used. The compression device (three chambers) was applied sequentially for 11 seconds with pressures of 45, 40, and 30 mm Hg at the ankle, calf, and thigh.
The allocation sequence was computer-generated with random block sizes and stratified according to three variables (six strata): age Ͻ80 years Ն80 years, surgical removal of the hematoma planned within 48 hours after referral, and admission in an intensive care unit without surgical removal. Allocation was concealed in sequentially numbered, sealed, opaque envelopes kept at the coordinating office. Envelopes were opened sequentially after participants' details were written on the back of the envelope. Cardboard inside the envelope ensured opacity. The research nurse assigned participants to their groups.
Outcomes. The primary endpoint with respect to efficacy was a combined criterion evaluated at day 10 Ϯ 2 after randomization: 1) a symptomatic DVT of the lower limbs (either below or above the popliteal trifurcation) objectively confirmed by compression ultrasonography (CUS) or 2) a nonfatal PE documented by either a high-probability lung scan or a positive helicoidal CT scan or a positive angiography, 3) death-related to PE, and 4) asymptomatic DVT of the lower limbs detected by CUS on day 10.
Secondary endpoint was clinically overt VTE assessed at 30 and 90 days after randomization.
Sample size. Based on the results of trials performed in general surgery and neurosurgery, we hypothesized that the incidence of asymptomatic DVT or symptomatic VTE or death related to PE would be 30% in the ES group and that IPC could reduce the risk of VTE by 66%. To ensure 0.9 power to detect such a relative risk reduction at ␣ level of 0.05 (one-sided test), 75 patients were required for each study group, assuming that 15% of enrolled patients would be unavailable for primary endpoint.
Blinding. Participants and those administering the interventions were not blinded to group assignment. Conversely, those assessing the outcomes remained blinded to allocation group.
Care providers removed IPC and ES before the patient underwent CUS by a trained physician (L.B.). In addition, ultrasonography images were stored on videotapes and read by another skilled radiologist (J.F.G.) who was unaware of the patient's treatment assignment.
Medical records of all deceased patients were extensively reviewed in a blinded fashion by an independent committee (C.L., chair), which stated whether death was related to either a clearly identified cause not related to PE, probably or certainly related to PE, or PE could not be definitively ruled out as the leading cause. Any clues about assignment group were removed from medical records as well as the identity of the patient at the time of assessment.
Statistical analysis. Efficacy analysis was performed on an intention-to-treat basis. The frequencies of the combined primary outcome at day 10 were compared between groups using an exact one-sided Fischer test. Adjustment for stratification variables used Cochran-Mantel-Haenszel test. Relative risk and absolute risk reduction were computed with their 95% confidence intervals (CIs). A logistic regression model was used to take into account potential imbalance in baseline characteristics. In all, 89 patients had exclusion criteria and 151 were included: 77 were randomly assigned to wear ES alone and 74 were randomly assigned to ES plus IPC. All randomized patients received the intended treatment. We analyzed the primary outcome for the 133 patients who completed the study. Eighteen patients (11.9%) were not evaluated (eight in the ES group and ten in the ESϩIPC group) because they left Brest Hospital without having a CUS. However, all 151 included patients were followed up for secondary outcome. Data were collected for all patients at 1 month and four patients (2.6%) were lost to follow-up at 3 months. Table 1 shows the characteristics of the study population. Both groups had similar characteristics except for age (p Յ 0.01), known arterial hypertension (p Յ 0.05), and varicose veins (p ϭ 0.06). Very few overweight people were included: only 10 patients (6.6%) weighted Ն90 kg.
Results. From
There was no symptomatic VTE in any group. Fourteen patients died before having a venous CUS (eight in the ES group, six in the ES ϩ IPC group) but no death was definitely related to PE according to the adjudication committee. All qualifying events were asymptomatic DVT detected by venous CUS: 11 (15.9%) in the ES group (three proximal and eight distal) and three (4.7%) in the ES ϩ IPC group (all distal) (figure 2). ES ϩ IPC reduced the risk of asymptomatic DVT compared to ES alone (relative risk [RR] 0.29; 95% CI 0.08 to 1.00; p ϭ 0.03). Absolute risk reduction was 0.11 (95% CI 0.00 to 0.22). Adjustment for age, hypertension and varicose veins using a logistic regression model displayed similar result (odds ratio [OR] 0.31; 95% CI 0.08 to 1.22).
During the 3-month follow-up, only two patients (one patient in each group) experienced a clinically overt and well-documented VTE.
Random allocation was stratified according to three variables. Few patients aged Ն80 years were included (n ϭ 11). Therefore, the six strata were grouped into three (table 2). Adjustment for stratification variables did not alter the result.
The adjudication committee stated that no death arising before day 10 was related to PE. For 13 patients, a clear cause of death was identified. For one patient, PE could not definitively be ruled out as the leading cause of death because no autopsy was performed. However, this patient had a metastatic lung cancer with a known lymphangitic carcinomatosis. This patient was allocated to ES ϩ IPC. Even if we considered this death as a qualifying outcome, IPC still reduced the incidence of VTE (RR 0.39; 95% CI 0.13 to 1.17). Out of the 18 nonevaluated patients at day 10, one patient died at 3 months in the ES ϩ IPC group, two patients experienced a symptomatic VTE (one in each group), and one patient was lost to follow-up in ES group. Assuming the worst hypothesis, there would have been 13 events in the ES group (11 asymptomatic DVT ϩ 1 symptomatic VTE ϩ 1 lost to follow-up) and five events in the ES ϩ IPC group (3 asymptomatic DVT ϩ 1 symptomatic VTE ϩ 1 death), leading to a relative risk estimate of 0.41 (95% CI 0.15 to 1.09).
Fourteen patients (18.9%) out of 74 patients allocated to IPC did not tolerate the device and stopped wearing it within 5 days after randomization. Twelve of them underwent CUS at day 10, which was positive in one patient.
Discussion. IPC combined with graded ES reduced the risk of asymptomatic DVT at day 10 by 71% compared to ES alone for patients with ICH. No proximal DVT was observed in those patients allocated to ES ϩ IPC. To our knowledge, in this particular clinical setting of acute ICH, no other randomized trial that aims to evaluate mechanical prophylaxis of VTE has been published so far.
IPC devices encompass a wide range of systems: there are multichamber or monochamber devices acting toward either the whole leg or only the calf, applying pressure either sequentially or uniformly; lastly there is also a plantar compression system. The protective effect of IPC may be ascribed to an increase of blood flow velocity. 12, 13 Studies comparing various devices are scarce 13, 14 and we cannot state that all devices have the same properties.
We are not aware of randomized trials evaluating mechanical devices for patients with ICH. However, relevant findings are available from stroke patients and from neurosurgical patients.
Stroke patients have a high risk of DVT in the paralyzed lower extremity. 2 In a nonrandomized prospective study of 681 ischemic stroke patients, the combination of heparin with ES and IPC was associated with fewer symptomatic DVT and PE than heparin with ES alone. 15 Patients undergoing elective neurosurgical procedures are also known to be at increased risk of postoperative venous thromboembolism. 10, 11 Mechanical methods of prophylaxis are interesting because of concerns about intracranial or spinal bleeding. IPC appears to be effective at preventing asymptomatic DVT in elective neurosurgery, with an average risk reduction of 68% compared with controls: average incidence decreased from 21% to 7%. [5] [6] [7] [8] [9] [10] [11] Most trials used calf-length IPC and fibrinogen uptake test (FUT) to detect venous thrombosis. Only one randomized trial compared ES to ES ϩ IPC in neurosurgical patients 9 and found no advantage for the association: DVT occurred in 7 of 78 patients (9.0%) in ES ϩ IPC group and in 7 of 80 patients (8.8%) in ES group. Routine postoperative surveillance using CUS of 2,643 neurosurgery patients who had undergone prophylaxis with ES and IPC found DVT in 6%, 16 but the rate in similar patients without prophylaxis is unknown. However, a recent metaanalysis found that heparin has been shown to be effective for prophylaxis of VTE in elective neurosurgery without excessive bleeding. 17 In 68 patients with ICH, early use of heparin for the prevention of thromboembolic complications was safe. 4 Nevertheless, these results were not confirmed by other trials and anticoagulant prophylaxis in patients with ICH is still discussed. Anticoagulation associated to IPC was evaluated in neurosurgery in patients undergoing craniotomy with good efficacy and safety, 18, 19 but no results are available concerning ICH. In this setting the 7th ACCP consensus, based on data from other settings, recommends mechanical prophylaxis with ES or ES ϩ IPC. 3 Mechanical prophylaxis is also proposed in intensive care units when the bleeding risk is of concern. 20 The trial included well-targeted patients with a fairly good inclusion rate (63%) and few patients (2.6%) were lost to follow-up. We used wellrecognized combined criteria as a primary outcome. All events were independently validated.
All qualifying events in our trial were asymptomatic DVT detected by CUS and most of them were distal. First, our trial was not designed to demonstrate a significant reduction of symptomatic VTE or death. Analyzing such clinical outcome would have been more clinically relevant but would have required a large sample and the feasibility of such a trial is highly questionable. Second, CUS has positive points: it is noninvasive, painless, and more feasible than venography, which was unavailable in about 15% to 30% of patients in some studies. 21, 22 Although CUS was found to be less sensitive than venography, 23 we previously reported that CUS had high sensitivity and specificity for the detection of asymptomatic DVT, and so displayed good qualities as a screening tool. 24 Moreover, in present study, videotapes were blindly reviewed. CUS has been used as diagnostic test for DVT in prevention trials. 19, 25 Lastly, below-knee DVT is clinically relevant because of the risk of proximal extension when untreated and the possibility of pulmonary embolism. 26 Sources of potential biases were taken into account by stratification and a multivariate analysis handled potentially remaining confusion. Eighteen patients (11.9%) were not evaluated but they were followed up to 3 months and sensitivity analysis did not substantially alter the result.
IPC was generally well accepted by the patients. Some of them did not tolerate the relentless inflation or noise. Eleven out of the 14 patients who did not tolerate IPC were hospitalized in the neurosurgery unit without impaired consciousness. On the other hand, the device was highly acceptable for intensive care unit (ICU) patients who were comatose or sedated. According to the balance efficacy-tolerance, there is a probably greater interest for IPC in ICU patients. Proper use of the device by nursing staff was quite high, but one could expect a lower compliance in daily practice than in a clinical trial. IPC has its contraindications including trauma of the lower limbs and arteriopathy, which were exclusion criteria. Lastly, significant costs and the inability to continue prophylaxis after hospital discharge limit the utility of IPC.
Our study is the first randomized trial evaluating a mechanical prophylactic method for patients with ICH. Asymptomatic DVT was detected at day 10 by CUS in 15.9% of patients wearing ES alone. IPC significantly decreased the occurrence of asymptomatic DVT to 4.7%. Although all qualifying events were asymptomatic DVT, in a risk-to-benefit perspective, IPC may be beneficial for patients with ICH at least as an initial prophylaxis and therefore should be considered.
